Fengmin Xi
Mr. Fengmin Xi joined InxMed in March 2023 as DMPK Director. Fengmin has more than 10 years of R&D experience in DMPK, toxicology and medicinal chemistry, additionally, along with rich investment and financing skills in biotechnology. He previously employed in a biotech boutique investment bank, HollyHigh, and engaged in investment and financing for biotech and CXO company. Prior to that, he worked for WuXi AppTec (603259.SH/2359.HK) and Medicilon (688202.SH) in clinical bioanalysis, preclinical DMPK and toxicology.
He held the Ph.D. in medicinal chemistry at Peking Union Medical College and Tsinghua University.

We invent personalized medicines with global impact, and turn innovation in China to life saving therapies for the world
QUICK LINKS
CONTACT US
Tel: +86 25-58251030
Email: office@inxmed.com
Office address: 73 Tanmi Road Block D-2, 3rd Floor Jiangbei New District, Nanjing
MESSAGE
Follow Us:
CopyRight © 2022 InxMed All Rights Reserved.
Message